Obi Pharma, Inc. · TPEX:4174
Obi Pharma — 2024 BioAsia – Investment Summit
9 slides from Obi Pharma's conference presentation, Jul 25, 2024
Slide 1: OBI Pharma: Innovation and Optimism
OBI Pharma Innovation and Optimism 2024 BioAsia – Investment Summit July 25, 2024 © 2024 OBI Pharma Inc. All Rights Reserved.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as “believes,” “expects,” “anticipates, ” “ projects,” “ intends,” “should,” “seeks,” “estimates,” “ future ,” “or similar expressions or by discussio
Slide 3: OBI Management Philosophy
OBI Management Philosophy • New drug development: a 5-year plan OBI-822, OBI-992, GlycOBI®, and EndoSymeOBI® • Agile strategy: Licensing and partnership Portfolio, platform, and enzyme • Talent: renewal and growth Strong succession plan 3 July 2024
Slide 4: Experienced Drug Developers: Deep Expertise in Carbohydrate Chemistry
Experienced Drug Developers Deep Expertise in Carbohydrate Chemistry TARGETS & MODALITIES Globo H, TROP2, Nectin-4, HER2, AKR1C3 and other potential targets Active Targeted Immunotherapy Prodrug ADC BsADC Antibody Drug Conjugates Bispecific ADC 4 July 2024
Slide 5: Oncology Pipeline with a Focus on ADC
Oncology Pipeline with a Focus on ADC MODALITY/ RECRUITING COMPOUND TARGET TUMOR TYPE DISCOVERY P1 P2 P3 PLATFORM REGION(S) Adagloxad Active Asia, AUS, EUR, Globo H Breast (TNBC) Simolenin Immunotherapy S. Africa, SA, USA Active OBI-833 Globo H Lung (NSCLC) Taiwan Immunotherapy Liver (HCC) OBI-3424
Slide 6: Adagloxad Simolenin Global Phase III TNBC Trial
Adagloxad Simolenin Global Phase III TNBC Trial ◼ Randomized, open-label ◼ Patients with high-risk, ◼ Primary endpoint: ◼ Ada Sim + SOC* as study early-stage Globo H- Design Objective IDFS (invasive Population treatment positive triple negative disease-free survival) ◼ SOC as control breast cancer *
Slide 7: Proprietary Glycan Site-Specific ADC Platform
Proprietary Glycan Site-Specific ADC Platform ® • PCT/US2023/074849, 2023 • Novel Linker-payload, US provisional application, 2023 ® • Poster presentation AACR, San Antibody Glycan Engineering Technology Diego US, Apr. 2024. JACS Au, DOI: 10.1021/jacsau, 2024 Fuc Novel Linker-Payload Technology Link
Slide 8: Plug-&-Play with GlycOBI
Plug-&-Play with GlycOBI® GlycOBI® DAR8 ADC Bispecific ADC Breast Cancer – JIMT-1 Herceptin-resistant CDX model Superior in vivo antitumor activity TGI (%) vs Enhertu® 3 mg/kg Single dose Vehicle Enhertu® (AZ/Daiichi Sankyo) HER2 63 ® ADC 153 HER2 GlycOBI ® ADC GlycOBI® DAR4 ADC Colorectal Cancer –
Slide 9: ASK: 2024 H2 Fundraising
OBI Partnering Strategy Innovative Cancer Portfolio & Platforms ASK: 2024 H2 FUNDRAISING • Regional or Global Licensing • Commercial partnerships Contact us: • R & D combination study collaborations info@obipharma.com • Strategic alliances Antibody-drug conjugates Targeted Active Immunotherapy Portf